{"id":"immediate-cervarix-delayed-menveo-vaccine","safety":{"commonSideEffects":[{"rate":"50-70","effect":"Injection site pain/erythema"},{"rate":"20-30","effect":"Headache"},{"rate":"10-20","effect":"Myalgia"},{"rate":"10-20","effect":"Fatigue"},{"rate":"5-15","effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cervarix is a bivalent HPV vaccine that stimulates immune response against HPV types 16 and 18, which cause cervical cancer. Menveo is a meningococcal conjugate vaccine that provides protection against serogroups A, C, W, and Y by inducing antibody responses against meningococcal polysaccharide capsules. The delayed administration schedule allows for sequential immune priming against both pathogens.","oneSentence":"This is a vaccination regimen combining two separate vaccines: Cervarix (HPV vaccine) given immediately and Menhibrix or Menveo (meningococcal vaccine) given on a delayed schedule to provide protection against human papillomavirus and meningococcal disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:48:16.300Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of cervical cancer and precancerous lesions caused by HPV types 16 and 18"},{"name":"Prevention of meningococcal disease caused by serogroups A, C, W, and Y"}]},"trialDetails":[{"nctId":"NCT03675256","phase":"PHASE4","title":"The KEN SHE Study on HPV-vaccine Efficacy","status":"UNKNOWN","sponsor":"Massachusetts General Hospital","startDate":"2018-12-19","conditions":"Papillomavirus Infections","enrollment":2275}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"immediate Cervarix, delayed MenVeo vaccine","genericName":"immediate Cervarix, delayed MenVeo vaccine","companyName":"Massachusetts General Hospital","companyId":"massachusetts-general-hospital","modality":"Biologic","firstApprovalDate":"","aiSummary":"This is a vaccination regimen combining two separate vaccines: Cervarix (HPV vaccine) given immediately and Menhibrix or Menveo (meningococcal vaccine) given on a delayed schedule to provide protection against human papillomavirus and meningococcal disease. Used for Prevention of cervical cancer and precancerous lesions caused by HPV types 16 and 18, Prevention of meningococcal disease caused by serogroups A, C, W, and Y.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}